All In Biotech

Drug Trial Radar · NCT07003984

A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.

A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled, Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children 1 to <12 Years of Age

Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 720 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

720

Planned (sponsor's estimate)

Start

Jun 5, 2025

Primary completion

Sep 2028

Study completion Sep 2028

Sponsor

Lead sponsor
Bavarian NordicIndustry
Sponsor type
Industry
First posted
Jun 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 1 year, up to 11 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this multi-center, randomized, double-blind, placebo-controlled study is to evaluate the safety and immunogenicity of CHIKV VLP Vaccine in children 1 to \<12 years of age.

Conditions

  • Chikungunya Virus

Interventions

  • CHIKV VLP vaccineBiological

    CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide (Alhydrogel®) adjuvant 2%

  • PlaceboBiological

    Placebo is comprised of formulation buffer

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety Endpoint 3: Incidence of AESI, MAAEs, and SAEsTime frame: From vaccination through the end of the trial, planned to be Day 732 for study completers.
  2. Primary Immunogenicity Endpoint: Day 22 anti-CHIKV SNA seroresponse rate in seronegative childrenTime frame: Study Day 22, 21 days after vaccination with CHIKV VLP vaccine or placebo.
  3. Safety Endpoint 2: Incidence of unsolicited AEs through Day 29Time frame: From vaccination on Day 1 through Day 29, 28 days after vaccination with CHIKV VLP vaccine or placebo.

Locations

15 sites in 3 countries. Site status is shown where the registry gives one.

  • ARK Clinical Research, LLC

    Fountain Valley, California

  • Emerson Clinical Research Institute- DC

    Washington D.C., District of Columbia

  • Acevedo Clinical Research

    Miami, Florida

  • Hope Research Network

    Miami, Florida

  • Velocity Clinical Research-Omaha

    Omaha, Nebraska

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • KidCare Pediatrics

    Beaumont, Texas

  • Velocity Clinical Research - Salt Lake City

    West Jordan, Utah

  • CARE CT Group Inc.

    Dasmariñas, Cavite, Philippines

  • HIMC Research and Development on Medical Sciences

    Imus, Cavite, Philippines

  • University of the Philippines-Philippine General Hospital

    Manila, Cavite, Philippines

  • Silang Specialist Medical Center

    Silang, Cavite, Philippines

  • University of Perpetual Help DALTA Medical Center, Biomedical Research Institute

    Las Piñas, National Capital Region, Philippines

  • Institute of Child Health and Human Development, University of the Philippines

    Manila, National Capital Region, Philippines

  • CMRC Headlands LLC

    San Juan, Puerto Rico, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.